FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

• Principais autores: Shike Yan (Autor), Bing Zhang (Autor), Jingwen Feng (Autor), Haigang Wu (Autor), Namin Duan (Autor), Yamin Zhu (Autor), Yueliang Zhao (Autor), Shuang Shen (Autor), Kai Zhang (Autor), Wenhui Wu (Autor), Ning Liu (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been used as a first-line treatment for patients harboring with EGFR mutations in advanced NSCLC. Nevertheless, the drug resistance aft...